The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. / Cunha-Bang, C da; Kirkby, N; Sønderholm, M; Sørensen, S S; Sengeløv, H; Iversen, M; Rasmussen, A; Gustafsson, F; Frederiksen, C M; Kjaer, J; Lepri, A Cozzi; Lundgren, J D.
In: American Journal of Transplantation (Online), Vol. 13, No. 2, 02.2013, p. 458-66.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection
AU - Cunha-Bang, C da
AU - Kirkby, N
AU - Sønderholm, M
AU - Sørensen, S S
AU - Sengeløv, H
AU - Iversen, M
AU - Rasmussen, A
AU - Gustafsson, F
AU - Frederiksen, C M
AU - Kjaer, J
AU - Lepri, A Cozzi
AU - Lundgren, J D
N1 - © Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.
PY - 2013/2
Y1 - 2013/2
N2 - (Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio
AB - (Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio
KW - Adult
KW - Cytomegalovirus
KW - Cytomegalovirus Infections
KW - Drug Resistance, Viral
KW - Female
KW - Foscarnet
KW - Ganciclovir
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Inhibitory Concentration 50
KW - Male
KW - Middle Aged
KW - Mutation
KW - Odds Ratio
KW - Organ Transplantation
KW - Phosphotransferases (Alcohol Group Acceptor)
KW - Prevalence
KW - Recurrence
KW - Risk Factors
KW - Time Factors
KW - Treatment Outcome
KW - Young Adult
U2 - 10.1111/ajt.12042
DO - 10.1111/ajt.12042
M3 - Journal article
C2 - 23282281
VL - 13
SP - 458
EP - 466
JO - American Journal of Transplantation
JF - American Journal of Transplantation
SN - 1600-6135
IS - 2
ER -
ID: 105597872